Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Genmab A/S ADR (NQ: GMAB ) 22.98 +0.02 (+0.09%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 2,087,791 Open 22.78 Bid (Size) 22.60 (2) Ask (Size) 23.43 (8) Prev. Close 22.96 Today's Range 22.73 - 23.09 52wk Range 22.52 - 32.89 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 12 Analysts Have This To Say About Genmab October 16, 2024 Via Benzinga NASDAQ:GMAB qualifies as a high growth stock and is consolidating. October 09, 2024 GENMAB A/S -SP ADR (NASDAQ:GMAB)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. Via Chartmill Performance YTD -28.43% -28.43% 1 Month -13.22% -13.22% 3 Month -17.34% -17.34% 6 Month -20.68% -20.68% 1 Year -22.99% -22.99% More News Read More NASDAQ:GMAB is an undervalued gem with solid fundamentals. October 08, 2024 Via Chartmill NASDAQ:GMAB, a growth stock which is not overvalued. October 07, 2024 Via Chartmill Jin Medical International, Nio And Other Big Stocks Moving Lower In Monday's Pre-Market Session September 23, 2024 Via Benzinga NASDAQ:GMAB is probably undervalued for the fundamentals it is displaying. September 17, 2024 Via Chartmill Expert Ratings For Genmab September 09, 2024 Via Benzinga NASDAQ:GMAB: a strong growth stock preparing for the next leg up?. September 03, 2024 Via Chartmill NASDAQ:GMAB is showing good growth, while it is not too expensive. August 26, 2024 Via Chartmill Decoding 10 Analyst Evaluations For Genmab August 20, 2024 Via Benzinga Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation. September 16, 2024 Via Chartmill Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial September 15, 2024 From Genmab A/S Via Business Wire TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma August 19, 2024 From Genmab A/S Via Business Wire Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock? August 05, 2024 Via Chartmill What 8 Analyst Ratings Have To Say About Genmab August 01, 2024 Via Benzinga What 8 Analyst Ratings Have To Say About Genmab July 15, 2024 Via Benzinga Genmab Announces Changes to its Executive Committee August 16, 2024 From Genmab A/S Via Business Wire On Holding Reports Mixed Q2 Results, Joins Tencent Music Entertainment And Other Big Stocks Moving Lower In Tuesday Pre-Market Session August 13, 2024 Via Benzinga GMAB Stock Earnings: Genmab Misses EPS, Beats Revenue for Q2 2024 August 08, 2024 Via InvestorPlace BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products August 05, 2024 Via Benzinga Exposures COVID-19 NASDAQ:GMAB, an undervalued stock with good fundamentals. July 01, 2024 Via Chartmill While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable. August 05, 2024 Via Chartmill Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced. July 15, 2024 Via Chartmill Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma June 28, 2024 From Genmab A/S Via Business Wire AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway June 27, 2024 Via Benzinga Exposures Product Safety Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
